Array Strikes New Deal For Cancer Drug With Longtime Partner Genentech, Taking $28M Upfront
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech gains a second compound that regulates cell cycle progression and Array receives cash to advance four in-house drugs through the clinic.